EU opens rare excessive pricing investigation

The European Commission has opened a formal investigation into Aspen following concerns that the drugmaker has unjustifiably increased the price of several anti-cancer medications, marking the enforcer’s first excessive pricing case in the pharmaceutical sector.

Get unlimited access to all Global Competition Review content